Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)


Domain Therapeutics

Domain Therapeutics receives a single digit multimillion development milestone payment from Merck for M1069 clinical development in immuno-oncology

Strasbourg, France – Montreal, Canada, June 28, 2022 – Domain Therapeutics, a biopharmaceutical company focusing on the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced that it obtained a single digit multimillion milestone payment from Merck as part of the €240m ($261m) milestone payments and undisclosed royalties collaboration and license partnership signed in 2017.

Read More »

Launch of Vik Colorectal in Spain

We are proud to announce the launch of Vik Colorectal in Spain! Developed with the institutional support of Pierre Fabre Group, our newest virtual companion will support patients and their loved ones living with colorectal cancer!

Read More »

Acticor Biotech obtains “PRIME” status from the European Medicines Agency for glenzocimab in the treatment of stroke

Paris, France, July 21, 2022 – 7:00 PM CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announced today that it has received “PRIority Medicines” status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.

Learn more

Subtle Medical Announces Partnership Expansion With Incepto

Subtle Medical, a healthcare technology company improving the quality and efficiency of medical imaging, announced they are expanding their partnership with Incepto, a leading platform of artificial intelligence solutions for radiology professionals in Europe, by offering their AI applications, SubtleMR and SubtlePET on Incepto’s platform.

Learn more

Latest Insights

42 start-ups through to Catapult 2022-23 semifinals

We are excited to today announce the 42 promising start-ups that will go through to the semifinals of EIT Health Catapult 2022-23. Each year, the competition showcases Europe’s most promising biotech, medtech and digital health start-ups to leading experts and investors. Many participants of the competition have gone on to excel in their respective fields.